02197.HK
Clover Biopharmaceuticals, Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 2.10
+3.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 52.2M | 3.4M | 38.4M | 39.3M | — |
| Cost of Revenue | 750.0M | 27.3M | 711.4M | 15.0M | 475.6M |
| Gross Profit | (697.9M) | (23.8M) | (672.9M) | 24.2M | (475.6M) |
| Operating Expenses | |||||
| R&D Expense | 349.2M | 155.5M | 183.4M | 649.9M | 1.5B |
| SG&A Expense | 144.6M | 65.2M | 40.1M | 107.2M | 113.1M |
| General & Admin Expense | 62.3M | — | 20.4M | 52.5M | 113.1M |
| Selling & Marketing Expense | 17.9M | — | 19.7M | 54.8M | — |
| Other Expenses | (9.8M) | 3.3M | 54.8M | 139.2M | 297.2M |
| Total Operating Expenses | 484.0M | 223.9M | 278.3M | 896.3M | 1.9B |
| Cost and Expenses | 1.2B | 251.2M | 989.6M | 2.6B | 2.4B |
| Operating Income (EBIT) | (1.2B) | (247.8M) | (951.2M) | (2.6B) | (2.4B) |
| Non-Operating | |||||
| Interest Income | 16.1M | 6.2M | 23.7M | 16.1M | 8.5M |
| Interest Expense | 194.9K | 367.2K | 5.8M | 18.7M | 5.9M |
| Net Interest Income | 15.9M | 5.8M | 17.9M | (2.6M) | 2.6M |
| Other Non-Op Income/Expense | 1.1B | 48.0M | 47.8M | 2.4B | (100.7M) |
| Non-Operating Income (excl Interest) | 3.5M | — | 3.6M | (752.3M) | 49.0M |
| EBT (Pre-Tax Income) | (69.9M) | (199.8M) | (903.4M) | (138.5M) | (2.5B) |
| Income Tax Expense | — | — | — | — | (229.0K) |
| Bottom Line | |||||
| Net Income | (66.3M) | (199.8M) | (903.4M) | (138.5M) | (2.5B) |
| Earnings from Cont. Ops | (66.3M) | (199.8M) | (903.4M) | (138.5M) | (2.5B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (66.3M) | (199.8M) | (903.4M) | (138.5M) | (2.5B) |
| Per Share | |||||
| Basic EPS | (HK$0.06) | (HK$0.16) | (HK$0.72) | (HK$0.11) | (HK$2.22) |
| Diluted EPS | (HK$0.07) | (HK$0.16) | (HK$0.72) | (HK$0.11) | (HK$2.22) |
| Revenue Per Share | HK$0.04 | HK$0.00 | HK$0.03 | HK$0.03 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.2B | 1.1B |
| Diluted Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.2B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | (1.1B) | (221.2M) | (916.5M) | (45.1M) | (2.4B) |
| D&A | 58.3M | 26.5M | 38.3M | 74.7M | 29.0M |
| EBIT | (1.2B) | (247.8M) | (954.8M) | (119.8M) | (2.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026